Ikbel Achour Selected Research

Circulating Tumor DNA

1/2022

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ikbel Achour Research Topics

Disease

6	Neoplasms (Cancer) 01/2022 - 01/2014
1	Inflammation (Inflammations) 01/2024
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024
1	Lung Neoplasms (Lung Cancer) 01/2024
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2022
1	Asthma (Bronchial Asthma) 11/2017
1	Squamous Cell Carcinoma of Head and Neck 01/2017
1	Circulating Neoplastic Cells 01/2016
1	Breast Neoplasms (Breast Cancer) 06/2015
1	Adenocarcinoma of Lung 11/2014
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2013
1	Alzheimer Disease (Alzheimer's Disease) 02/2009
1	Genomic Instability 10/2003

Drug/Important Bio-Agent (IBA)

4	RNA (Ribonucleic Acid)IBA 01/2017 - 11/2014
1	InterferonsIBA 01/2024
1	NivolumabIBA 01/2022
1	durvalumabIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2019
1	Granzymes (Granzyme)IBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2014
1	Immunoglobulin E (IgE)IBA 11/2013
1	Peptides (Polypeptides)IBA 02/2009
1	Amyloid beta-PeptidesIBA 02/2009
1	DNA (Deoxyribonucleic Acid)IBA 10/2003

Therapy/Procedure

4	Immunotherapy 01/2024 - 02/2019
2	Therapeutics 01/2022 - 01/2014
2	Precision Medicine 11/2017 - 06/2015